Enigma Biomedical Group
About Enigma Biomedical Group
Enigma Biomedical Group was founded to introduce a novel biotech-pharma model in Molecular Imaging and Medicine (MIM). The MIM concept unifies advanced diagnostics (such as PET/CT and near-infrared imaging, and gene/gene product analysis), with capabilities for state-of-the-art R&D for accelerated drug development and studying fundamental disease mechanisms. MIM is a multi-disciplinary philosophy, combining university and industry expertise, providing the environment for training, developing and deploying new technologies, and conducting clinical research. MIM provides a focal point for a paradigm shift from conventional medicine to “personalized medicine”. Enigma Biomedical Group and its affiliates are strategically aligned to deliver to the pharmaceutical industry and clinical research community a new model for drug development. This model is based on the merging of the fields of biology and imaging, in what is now commonly called molecular imaging. By combining the facilities and expertise already available with additional expertise, a new Contract Research Organization (CRO) model can be introduced into the market with the following business lines: · “Niche” radiopharmaceutical producer and distributor, with a network of Manufacturing and Distribution sites in the region. · Development of new and proprietary tracers making them available to clinical service providers. · CRO for traditional pharmaceutical companies to improve rates of drug discovery, and speed drug development and approval. This new CRO model will span drug development - from drug discovery to testing and approval - from the basic science level, through animal research to human clinical trials and integrate as a non-invasive imaging tool to test, evaluate and validate new tracers and therapeutics. To effectively deliver this strategy will require a multi-disciplinary team of subject matter experts and access to extensive facilities. It is envisioned that the ideal model would include a biopharmaceutical company; a research based company and collaboration with strategic institutional/academic centres.11 articles about Enigma Biomedical Group
-
Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer
2/13/2024
Enigma Biomedical USA announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer. Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
-
Enigma Biomedical Group Signs Agreement to License Novel Neuro Imaging Biomarkers From Janssen
8/31/2020
Enigma Biomedical Group (EBG) today announced execution of a Master Development, License and Option Agreement and two Project Agreements to evaluate novel neuroimaging biomarkers from Janssen Pharmaceutica N.V. (Janssen), part of The Janssen Pharmaceutical Companies of Johnson & Johnson. These agreements permit EBG to evaluate Janssen’s PET ligands, and if such evaluation is favorable, grant to EBG an option to negotiate an
-
Enigma Biomedical Group Announces Appointment of Michael Reitermann to Their Board of Directors
11/18/2019
Michael Reitermann’s passion for innovation and its commercialization has driven his extensive career in the healthcare industry.
-
Enigma Biomedical and Invicro Sign a Memorandum of Understanding to Co-Develop Synaptic Density Biomarker Imaging
9/21/2018
Enigma Biomedical Group (EBG) today announced a collaboration agreement with Invicro, a Konica Minolta Company and a leading provider of imaging services and software for research and drug development, to cooperate in the development of Synaptic Density Biomarker Imaging (“SDI”).
-
Enigma Biomedical Group and Invicro Sign a Collaboration Agreement
8/20/2018
Enigma Biomedical Group (EBG) today announced a collaboration agreement with Invicro
-
Enigma Biomedical Group and Yale Sign Memorandum of Understanding to License Novel Investigational Synaptic Density Imaging Biomarker Technology
3/21/2018
Understanding to License Novel Investigational Synaptic Density Imaging Biomarker Technology
-
Enigma Biomedical Group Forms Australian Subsidiary To Further Research Efforts
1/9/2018
Enigma Biomedical Group today announced the formation of Enigma Biomedical Australia to support it’s ongoing research projects in Australia.
-
Cerveau Technologies and Enigma Biomedical Group Sign Research Agreement with Centre for Addiction and Mental Health (CAMH), Toronto
11/20/2017
These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography scans for assessing the status and progression of neurofibrillary tangles in the brain.
-
Enigma Biomedical Group Signs Research Agreement With Austin Health
3/23/2017
-
Enigma Biomedical Group Signs Research Agreement With McGill University Research Centre For Studies In Aging
2/21/2017
-
Enigma Biomedical Group Signs Research Agreement With Biogen And Merck & Co. For Novel Tau Imaging Agent
7/26/2016